Partners AMR Insights
For its global activities AMR Insights is dependent on its highly valued partners.
Resistell proposes an alternative to culture based antibiogram, the current gold standard in antibiotic susceptibility testing. The rapid AST method is based on the detection of movement caused by living bacterial cells. Resistell was selected in the Top 3 Inventors category at the Swiss Technology Award 2018.
BiosparQ B.V. is a privately-held in vitro diagnostics company dedicated to providing a unique Technology called DigiTOF® that improves patient outcomes and lowers healthcare costs through enabling clinicians to speed up diagnosis of infections.
The Cirrus D20 system is a platform intended for the rapid and cost-effective detection and identification of infectious pathogens. DigiTOF® is based on MALDI-TOF Mass Spectrometry
applied on single bacteria isolated directly from patient material. Easy to use, overall less than
20 minutes turnaround time and low cost per test.
To make a difference in the lives of people globally through our innovative medicines, vaccines, and animal health products. We are committed to being the premier, research-intensive biopharmaceutical company and are dedicated to providing leading innovations and solutions for today and the future.
BSAC is a leading influencer of antimicrobial use globally, and has been since the Society was founded in 1971. BSAC has members across 6 continents and in 40 countries, with over 60,000 learners in 37,500 learner locations engaged in its open access e-learning programme. BSAC publishes the Journal of Antimicrobial Chemotherapy and JAC-Antimicrobial Resistance (JAC-AMR).
ILSE is a life science technology accelerator, business incubator and a science-driven research institute that works in partnership with innovators, affiliated academic and biomedical institutions. ILSE has joined the CARB-X Global Accelerator Network as an accelerator to provide knowhow, diagnostics expertise, business strategy and other support to CARB-X’s growing portfolio of innovative antibacterial development projects.